Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double‐blind, baseline‐controlled trial

Schrempf, Wiebke; Fauser, Mareike; Wienecke, Miriam; Brown, S. Lori; Maass, Antonia; Ossig, Christiana; Otto, K.; Brandt, Moritz; Löhle, Matthias; Schwanebeck, Uta; Graehlert, Xina; Reichmann, Heinz; Storch, Alexander

doi:10.1111/ene.13567

Cited by 28 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A double-blind, baseline-controlled study found that rasagiline may be beneficial to the sleep quality of PD patients with sleep disturbance. [34] Based on the result of the study, rasagiline is likely efficacious in improving insomnia in patients with PD.…”

Section: Insomniamentioning

confidence: 99%

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Liu

Wang

Zhan

et al. 2018

Chinese Medical Journal

View full text Add to dashboard Cite

Section: Insomniamentioning

confidence: 99%

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Liu

Wang

Zhan

et al. 2018

Chinese Medical Journal

View full text Add to dashboard Cite

“…SDB (cutoff AHI > 5/h) was detected in 73% of patients ( Supplementary Table S1 ) with 46% (12/26) of our patients classified as suffering from mild to moderate sleep-related breathing disorder (SDB, AHI > 5/h ≤ 15/h), whereas 27% (7/26) were found to have moderate SDB (AHI > 15/h ≤ 30/h). Patients with severe SDB (AHI > 30/h) were not recruited into the study according to the predefined exclusion criteria ( Schrempf et al, 2018 ).…”

Section: Resultsmentioning

confidence: 99%

“…From 29 patients initially enrolled between 2011 and 2014, two were excluded due to cognitive impairment [Parkinson Neuropsychometric Dementia Assessment (PANDA) score <18] and one due to diagnostic precariousness, thus, 26 PD patients were included in the analysis. Patients fulfilling PSG exclusion criteria {e.g., severe SDB [Apnea-Hypopnea Index (AHI) >30/h]} and patients with signs of atypical parkinsonian syndromes, deep brain stimulation, severe depression [Montgomery–Asberg Depression Scale (MADRS) >34], severe dementia, or other medical conditions interfering with study procedures as well as patients on medication influencing sleep, e.g., hypnotics and antidepressants, were excluded from the study [for details, please refer to Schrempf et al (2018) ]. Patients had to be on stable antiparkinsonian medication for at least 4 weeks prior to study inclusion.…”

Section: Methodsmentioning

confidence: 99%

“…The current work is a post hoc analysis of a single-center, double-blind, baseline-controlled clinical RaSPar trial, which was conducted by Technische Universität Dresden, Germany (EudraCT-no. : 2010-023756-8) according to the ethical principles of the Declaration of Helsinki and the German drug law (12th version, AMG) and was registered with ClinicalTrials.gov (NCT01442610) ( Schrempf et al, 2018 ). It was approved by the local institutional review board (Ethics Committee of the Technische Universität Dresden; EK161052011) and the German Federal Institute for Drugs and Medical Devices (BfArM).…”

Section: Ethics Statementmentioning

confidence: 99%

See 1 more Smart Citation

Sleep Disturbances and Sleep Disordered Breathing Impair Cognitive Performance in Parkinson’s Disease

et al. 2020

View full text Add to dashboard Cite

Background Sleep disturbances and impairment of cognitive function are among the most frequent non-motor symptoms in Parkinson’s disease (PD) with negative implications on quality of life of patients and caregivers. Despite the fact that sleep disturbances are a major issue in PD patients, only limited data are available regarding interactions of sleep disturbances and cognitive performance. Objective This post hoc analysis of the RaSPar trial was therefore designed to further elucidate sleep disturbances and their impact on cognition in PD. Methods Twenty-six PD patients with sleep disturbances were evaluated thoroughly including assessments of patients’ subjective and objective sleep quality by interview, questionnaires, and polysomnography (PSG). Cognitive performance was assessed by Parkinson Neuropsychometric Dementia Assessment (PANDA) and Test of Attentional Performance (TAP), and associations of sleep and cognitive function were evaluated. Results We did not detect differences in cognitive performance between patients with and without rapid eye movement (REM) sleep behavior disorder (RBD). Instead, cognitive impairment, particularly affecting cognitive domains attention, executive function/working memory, and semantic memory, was associated with impaired PSG-measured sleep quality (e.g., sleep efficiency) and sleep disordered breathing (SDB) (Apnea-Hypopnea Index > 5/h). Global cognitive performance was decreased in patients with SDB (PANDA score 23.2 ± 3.5 vs. 26.9 ± 2.2, P = 0.020, unpaired two-sided t -test). Conclusion Sleep apnea and other sleep disturbances impair cognitive performance in PD and should be evaluated in routine care, and treatment options such as continuous airway pressure therapy should be considered.

show abstract

“…Firstly, the replacement of lost dopamine with dopaminergic drugs in 24 is necessary. Adjunctive medications [33][34][35], infusion systems such as DuoDopa (carbidopa/levodopa) [36], continuous dopamine delivery treatments like the transdermal rotigotine patch [37][38][39][40][41], and oral extended release versions of dopamine agents [42,43] have shown signi cant promise in ameliorating wearing-off effects and symptom uctuations, in nocturnal as well as daytime symptoms. In a randomized, placebo-controlled study (the RECOVER trial, quality score, 93%), patients with unsatisfactory control of early morning motor symptoms were evaluated on the PDSS-2 and UPDRS III.…”

Section: Implications For Managing Nocturnal Symptomsmentioning

confidence: 99%

Social Listening – Revealing Parkinson’s Disease over Day and Night

Zhang¹,

Meng²,

Li³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Nocturnal symptoms in Parkinson’s disease and their related burdens on patients are often treated after management of daytime manifestations. In order to better understand the unmet needs of nocturnal symptoms management, we sought to analyze the characteristics of nocturnal symptoms and the burden of nocturnal-occurring motor and non-motor symptoms from patients’ perspectives.Methods: We used a contemporary Social Listening big-data technique to analyze large amounts of Parkinson’s disease symptoms in patient-doctor and patient-patient dialogues available from social media platforms in China. Frequency of nocturnal symptoms as a proportion of total dialogues per year and their relative negative sentiment were analyzed. As a contrast, overall symptoms (occurring at day or night) were also analyzed. Results: We found that share of voice for overall motor symptoms did not increase from 2016 to 2018 (79%, p = 0.5), but share of voice for non-motor symptoms was 69% in 2018, growing by 7% (p < 0.01), and motor complications was 9%, growing by 6% (p < 0.01), respectively. For nocturnal symptoms, 45% of the analyzed PD population reported nocturnal symptoms in 2018, growing by 6% from 2016 (p < 0.01). Share of voice for nocturnal-occurring motor symptoms was higher than non-motor symptoms. Non-motor symptoms evoked higher negative sentiment no matter whether they occurred during the day or night. For symptoms that can occur at either day or night, each nocturnal symptom was rated with a higher negative sentiment score than the same symptom during the day, regardless of the type of symptom (motor, non-motor, or motor complication).Conclusions: The growing share of voice and the greater negative sentiment of nocturnal symptoms from patients’ perspectives suggest that management of nocturnal symptoms is an unmet need of patients with Parkinson’s disease. A greater emphasis on detecting nocturnal symptoms and treating them with 24-hour care is encouraged.

show abstract

Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double‐blind, baseline‐controlled trial

Abstract: In patients with PD with sleep disturbances, rasagiline showed beneficial effects on sleep quality as measured by polysomnography. These effects were probably not related to motor improvement or translated into improved overall sleep quality perception by patients.

Cited by 28 publications

References 28 publications

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Sleep Disturbances and Sleep Disordered Breathing Impair Cognitive Performance in Parkinson’s Disease

Social Listening – Revealing Parkinson’s Disease over Day and Night

Contact Info

Product

Resources

About